{"preliminary_commentary":{"by_channel":{"x_thread":9},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06561607\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"NCT06561607","nct_id":"NCT06561607","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06561607. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Administered by intravenous drip, 7.5 mg/kg per dose, 21 days as a treatment cycle.","label":"TQB2102 for Injection","type":"EXPERIMENTAL"},{"description":"Based on each patient's condition and previous treatment history, the investigator will select one of the following chemotherapy drugs for treatment.\n\n* Capecitabine\n* Paclitaxel\n* Albumin Paclitaxel","label":"Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2028-12","type":"ESTIMATED"},"conditions":["Breast Cancer"],"enrollment":{"count":542,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"TQB2102 for Injection","otherNames":[],"type":"DRUG"},{"name":"Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-10","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","official_title":"A Randomized, Open, Parallel-Controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival (PFS) in subjects with HR-positive, HER2 low-expressing recurrent/metastatic breast cancer as assessed by Independent Review Committee (IRC)","timeFrame":"Up to 25 months"}],"references":[],"start_date":{"date":"2024-10-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer","url":"https://clinicaltrials.gov/study/NCT06561607"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06561607"}